Cytochrome b5 KO Mouse Models for Study of Drug Metabolism (New)
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of drug metabolism. This model is a valuable tool for the studying of cytochrome b5 in metabolism and the evaluation of drug efficacy, bioavailability and toxicity in vivo. Liver cells extracted from the mice (hepatic microsomes) could also be isolated and used to test new drugs in vitro.
Contact: Dr Maud Andre, mandre@CancerTechnology.com
 Further details can be accessed here
Cytochrome b5 KO Mouse Models for Study of Steatosis (New)
A mouse model has been developed, in which cytochrome b5 has been knockout in the liver. The loss of cytochrome b5 results in significant reduction of the P450 metabolism and the development of hepatic vesicular steatosis. The model phenocopies the genesis and progression of non-alcoholic steatosis. This model is a valuable tool for the studying of the role of cytochrome b5 in steatosis and the evaluation of new prophylactics or therapeutics for steatosis.
Contact: Dr Maud Andre, mandre@CancerTechnology.com
Further details can be accessed here
Novel Marker of Early ES Cell Differentiation
A novel cell surface marker that is able to determine both the pluripotency and early differentiation state of an ES cell population in a single, rapid, non-destructive assay. This marker is a valuable tool for a wide range of ES cell techniques. Well characterised monoclonal antibodies to mouse and human antigens are available.
Contact: Dr Tanya Moore, tmoore@CancerTechnology.com
Further details can be accessed here
Endothelial Tissue-specific and Inducible Cre Transgenic Mice (New)
Inducible Cre transgenic strains expressing the Cre-ER(T2) gene switch under the control of VECAD or BMX promoters. These mice can be crossed with mice carrying LoxP-flanked genes of interest to generate temporally controlled tissue-specific deletions upon tamoxifen treatment. Tamoxifen treatment of the VECAD-Cre-ER(T2) embryos induces Cre activity in >90% of endothelial cells of all arteries, veins and in the lymphatic system. Tamoxifen treatment of adult mice induces Cre activity only in smaller vascular beds. These mice may be used for study of genes involved in vascular development and pathological angiogenesis in adult mice. Tamoxifen treatment of the BMX-Cre-ER(T2) mice induces Cre activity in arterial but not venous endothelial cells. These mice may be useful for study of genes involved in pathological arterial conditions, including artherosclerosis.
Contact: Dr Laura Fletcher, lfletcher@CancerTechnology.com
Further details can be accessed here
Microorganism Detection and Profiling
A new genomic tool for rapid, high throughput, accurate and cost effective identification of microorganisms has been developed. The technology is independent of culture techniques and facilitates the identification of pathogenic organisms in complex biological samples and environmental isolates. The invention also enables the identification of novel organisms and differentiates between closely related bacterial species and strains.
Contact: Dr Adrian Ibrahim, aibrahim@CancerTechnology.com
Transposon Mediated Genomic DNA Integration
Non-exclusive rights are available to a technology enabling the integration of DNA into host genomes across a variety of species, using transposons from the Tc1/Mariner family derived from Drosophila and C. elegans. Applications include gene therapy including stem cell research, gene tagging and genotype/phenotype analysis.
Contact: Dr Anne Horgan, ahorgan@CancerTechnology.com
TIRF: Microscope Test Slide
A test slide for Total Internal Reflection Fluorescence (TIRF) microscopes has been developed which mimics the features of a typical biological sample. It is anticipated that the test slide will find utility in such tasks as comparison of performance between different imaging systems, performance optimisation of a newly installed system, and the long term quality control of system performance.
Contact: Dr Phil Masterson pmasterson@CancerTechnology.com
Further details can be accessed here
CyMap: A Novel Miniature Cell Imaging Device
‘CyMap’ is a novel CCD-based cell imaging system with potential applications in automating a wide-range of live cell-based assays. The simple system utilises only low-cost components, is readily miniaturised and can be used inside a standard tissue culture incubator. Furthermore, the imaging modality has great potential for incorporation into lab-on-a-chip devices and integration with microfluidic platforms. The device can be used to monitor a wide range of cellular assays including cell number, cell division, colony formation, wound healing and migration. A patent application covering the CyMap technology has been filed and an exclusive multi-territory license is available to further develop and commercialise the technology.
Contact: Dr Laura Fletcher, lfletcher@CancerTechnology.com
Further details can be accessed here
Transgenic Mice and Cell Lines
CRT has a portfolio of transgenic mice encompassing conditional knock-ins and knock-outs and animal models derived from these sources. Noteworthy examples include two independent psoriasis models, BRCA1 and BRCA2 breast cancer models and a metastatic breast cancer model. A portfolio of these cell lines is also available for licensing, including TR146, a cell line that represents a unique in vitro model of human buccal mucosa. Copies of the Transgenic Mice and Cell Lines catalogue are available online.
Contact: Reagents@CancerTechnology.com
Antibody Portfolio
CRT's antibody portfolio currently consists of over 450 antibodies. Hybridomas are available for licensing in the fileds of research and in vitro diagnostics, and purified antibody is supplied for research purposes on a sales basis. Copies of the antibody portfolio are available both on request and online in a searchable format, providing a full technical profile for each antibody. Click here for the online version.
Contact: Reagents@CancerTechnology.com
|
